Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) – Research analysts at Zacks Research reduced their Q1 2023 EPS estimates for shares of Teva Pharmaceutical Industries in a report issued on Tuesday, September 20th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $0.53 per share for the quarter, down from their previous estimate of $0.54. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q3 2023 earnings at $0.56 EPS, Q4 2023 earnings at $0.66 EPS, FY2023 earnings at $2.32 EPS and Q2 2024 earnings at $0.61 EPS.

Several other research analysts have also recently weighed in on TEVA. StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, June 17th. The Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the company a "neutral" rating in a research report on Tuesday, August 2nd. Bank of America raised shares of Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating and boosted their price target for the company from $10.00 to $13.00 in a research report on Friday, August 5th. Finally, UBS Group initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, June 13th. They set a "neutral" rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $10.67.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last released its earnings results on Tuesday, July 26th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.09. Teva Pharmaceutical Industries had a negative net margin of 6.83% and a positive return on equity of 25.68%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.82 billion.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the company's stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $10.07, for a total value of $558,885.00. Following the transaction, the chief financial officer now owns 9,376 shares of the company's stock, valued at $94,416.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, VP David Matthew Stark sold 58,163 shares of the stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $9.04, for a total transaction of $525,793.52. Following the sale, the vice president now owns 2,974 shares of the company's stock, valued at $26,884.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Eliyahu Sharon Kalif sold 55,500 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $10.07, for a total transaction of $558,885.00. Following the sale, the chief financial officer now directly owns 9,376 shares in the company, valued at approximately $94,416.32. The disclosure for this sale can be found here. 0.82% of the stock is currently owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in the business. Cigna Investments Inc. New lifted its position in shares of Teva Pharmaceutical Industries by 5.0% during the second quarter. Cigna Investments Inc. New now owns 21,575 shares of the company's stock worth $163,000 after purchasing an additional 1,024 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of Teva Pharmaceutical Industries by 3.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 37,645 shares of the company's stock worth $292,000 after buying an additional 1,307 shares during the period. National Bank of Canada FI increased its stake in shares of Teva Pharmaceutical Industries by 1.3% during the first quarter. National Bank of Canada FI now owns 109,526 shares of the company's stock worth $1,025,000 after buying an additional 1,392 shares during the period. Morningstar Investment Services LLC increased its stake in shares of Teva Pharmaceutical Industries by 5.5% during the first quarter. Morningstar Investment Services LLC now owns 26,631 shares of the company's stock worth $245,000 after buying an additional 1,395 shares during the period. Finally, Ensign Peak Advisors Inc increased its stake in shares of Teva Pharmaceutical Industries by 3.4% during the fourth quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company's stock worth $367,000 after buying an additional 1,500 shares during the period. Institutional investors and hedge funds own 46.22% of the company's stock.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Stories

• Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Is Ford Rolling To A Rebound After Its Q3 Warning
• Has AMD stock stock fallen too far?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.